CASE STUDY ADULT CASES OF ONYCHOMYCOSIS. Warren S. Joseph, DPM, FIDSA
|
|
- Eunice Curtis
- 5 years ago
- Views:
Transcription
1 ADULT CASES OF ONYCHOMYCOSIS Warren S. Joseph, DPM, FIDSA BACKGROUND (CASE 1) A 41-year-old woman presented with no complaints of pain, but she was concerned about discoloration of her toenails. She has a black belt in karate and works as a karate teacher. She works out in her bare feet and is embarrassed by the condition of her toenails. She had approximately 25% to 30% distal involvement in her toenail, with no other nail involvement (Figure 1A). 1 The nail was not particularly thickened, just discolored. The patient had mild disease with no nail thickening. Some clinicians may have considered several approaches for this patient, such as watchful waiting (ie, waiting to see if the nail grows out normally and debride if necessary), debridement plus topical antifungal cream/solution (prescription or over-the-counter [OTC]), ciclopirox nail lacquer with or without debridement, or oral terbinafine with or without debridement. Although these all are essentially reasonable treatment approaches, watchful waiting is almost never recommended. Debridement would be a minimal and beneficial first step. Ciclopirox lacquer would be a reasonable first treatment because the patient s infection is confined. Oral medication also could be a first-line treatment, but some patients may choose to start with a topical agent, possibly because of concerns about oral medications, drug-to-drug interactions, or potential cost issues, depending on their insurance coverage. I elected to prescribe ciclopirox lacquer only. I saw this patient at her karate school, thus I was unable to perform debridement. She was a motivated patient, and the ciclopirox lacquer cured the infection. At the 3-month follow-up visit, the patient showed a 100% clinical cure of onychomycosis (Figure 1B). one nail, but he had some involvement in other nails (Figure 2). 1 It was the first time he had seen a physician for this infection. He had no discomfort and minimal nail thickening, but he was concerned because the infection was spreading. The hallux nail showed some involvement down to the level of the lunula. The patient s medical history reflected no other diseases. Figure 1A. 41-Year-Old Woman at Presentation Figure 1B. 3-Month Follow-Up BACKGROUND (CASE 2) A 75-year-old man came to the Veterans Administration (VA) hospital with 80% involvement of S614 Vol. 5 (6D) June 2005
2 Debridement alone or debridement plus a topical antifungal preparation would be insufficient for this patient. The infection had progressed to such a degree that pharmacotherapy was needed. A good treatment for this patient would be oral terbinafine alone, but I prefer the combination of oral terbinafine and ciclopirox lacquer. Although this patient did not have a severe case of onychomycosis, oral therapy would ensure more aggressive treatment. If the patient were diabetic, combination therapy would be warranted because the sequalae are more serious and more frequent in patients with diabetes mellitus. In my experience, virtually all patients with onychomycosis have coexisting tinea pedis (fungal infection of the skin). In fact, onychomycosis usually starts as tinea pedis and progresses into the hyponychium if there has been a trauma that broke the seal between the nail and the nail bed. The fungus then accesses the nail bed stratum corneum and causes onychomycosis. Tinea pedis usually can be easily treated, but onychomycosis will require treatment because it can act as a reservoir that reinfects the skin, creating an unending cycle of infection. For this patient, the only disadvantage to treating tinea pedis and onychomycosis was buying 3 different medications, but the investment would be worth the cost to prevent future or continuing infections. BACKGROUND (CASE 3) A 37-year-old patient with clinical AIDS and who tested positive for human immunodeficiency virus (HIV) returned to the clinic because he was concerned about a rapidly spreading nail infection. At his first clinic visit, his nail showed a small area of involvement, but the infection had spread in 1 month to most of his nail. The infection remained only within the hallux nail (Figure 3). 1 He was diagnosed with proximal subungual onychomycosis (PSO). Proximal subungual onychomycosis is the most common presentation of onychomycosis among patients with HIV. PSO has a unique presentation, as compared with the other types of onychomycosis: It starts at the eponychium (as opposed to the hyponychium) and spreads proximal to distal (as opposed to distal to proximal with other onychomycotic infections). This patient did not appear to have white superficial onychomycosis. Debridement would be a minimal first step in treatment, especially in a patient with HIV. If this patient did not have HIV, debridement and a topical antifungal, such as ciclopirox lacquer, may be sufficient. However, this patient will require more aggressive treatment because this is not a superficial infection. Systemic therapy may be needed. Terbinafine plus ciclopirox lacquer probably is the best treatment option. Also, with patients who are HIV positive, CD4 levels correlate with the activity of fungal infection. When CD4 counts are low, the infections progress more rapidly. However, with the currently available treatments for HIV infection, CD4 counts can be maintained at higher levels, thus the response should be similar to that for a person without HIV. Figure Year-Old-Man Figure Year-Old Patient with Clinical AIDS Advanced Studies in Medicine S615
3 BACKGROUND (CASE 4) A 70-year-old man who was seen at the VA hospital had severe pain from toenail infections. He was unable to wear shoes, and there was significant involvement (with marked thickening) of all of his toenails (Figure 4). 1 He was taking the following medications: atorvastatin 20 mg/day, aspirin 65 mg/day, hydrochlorothiazide 25 mg/day, and bupropion XL 300 mg/day. Debridement alone would not be a sufficient treatment, nor would the use of topical antifungal cream or solution. Because of the extensive involvement of all of the toenails, systemic therapy was necessary. Oral terbinafine with or without debridement could be a reasonable approach. A study by Gupta and Lynch has recently shown that combination Figure Year-Old Man Figure 5. A 55-Year-Old Man therapy in vivo can offer synergistic benefits not found with terbinafine or ciclopirox lacquer alone. 2 I recommend treatment with a combination of oral terbinafine and ciclopirox lacquer. Because of the multiple medications, some physicians may be concerned about drug interactions when using oral antifungal agents. Although there are significantly more interactions possible with itraconazole, terbinafine should not have a clinically significant interaction with any of the concomitant medications. There is a theoretical interaction possible with bupropion, a selective serotonin reuptake inhibitor (SSRI). The patient should be observed for any signs of increasing levels of that drug. BACKGROUND (CASE 5) A 55-year-old man was seen at the VA hospital with a severe infection but with no pain or itching. He came to our office at his wife s request. He had trouble cutting his toenails and had asked his wife to do it for him. His toenails had become so thick that the wife could no longer cut them (Figure 5). The patient also has severe tinea pedis that he treated with OTC topical creams, which were ineffective. This patient had a classic case of onychomycosis: no pain, no itching. Many patients with onychomycosis are unaware that they have coexistent tinea pedis infection. Patients usually complain of dry skin that will not resolve with any amount of moisturizer. When patients have infected toenails, the clinician should examine the skin of the foot and between the toes to look for signs of tinea pedis. In fact, onychomycosis starts as tinea pedis, thus the coexistence of this infection is not surprising. This patient already had tried topical agents that did not treat the tinea pedis, thus more aggressive treatment is necessary. Debridement alone would not be sufficient. Because of the extensive involvement and thickening of all nails, systemic therapy is necessary. Oral terbinafine with or without debridement is a reasonable approach; however, as with Case 4, the Gupta and Lynch data support a combination treatment approach. 2 I recommend oral terbinafine with ciclopirox lacquer. Maintenance therapy must be discussed with this patient. Several studies have shown relapse rates of onychomycosis ranging from 22% to 66% up to 3 years after treatment. 3-6 S616 Vol. 5 (6D) June 2005
4 CLINICIAN INTERVIEW Warren S. Joseph, DPM, FIDSA, has been appointed as Consulting Editor to Podiatry Management. Dr Joseph currently serves as editor of the Journal of the American Podiatric Medical Association and is an internationally recognized authority on onychomycosis and infectious diseases of the feet. He is also Adjunct Associate Professor, Internal Medicine, Section of Infectious Diseases, Temple University School of Medicine, Philadelphia, Pennsylvania. A senior clinical editor for Advanced Studies in Medicine (ASiM) interviewed Dr Joseph about diagnosing and managing onychomycosis in adult patients. ASiM: In Cases 1 and 2, you listed debridement as a good first step but not sufficient as a total treatment. In which cases would debridement be sufficient as treatment? Dr Joseph: Debridement does nothing to specifically address the fungus, but it will help the nail look better and be less painful for the patient. There will be less pressure because the nail won t be as thick, thus debridement does serve an important purpose. Debridement is recommended with ciclopirox topical nail lacquer to improve results, and there are some recent data showing that debridement in combination with oral antifungals may at least increase the efficacy. In the study, terbinafine alone was compared to terbinafine plus debridement; results showed there was some increased improvement with debridement. Debridement also improved the patients quality of life. The data are from the IRON-CLAD study, which is not yet published but was presented at the Midwestern Podiatry Meeting. Therefore, it certainly could be assumed that the same results would occur with the use of topical antifungals debridement may enhance their efficacy. Debridement is an important adjunct of palliative therapy, but it does not cure or treat the fungus. ASiM: In Case 2, you mention the importance of treating tinea pedis. What are the treatment options? Dr Joseph: Tinea pedis can be treated in 2 ways: topically and orally. There are several effective topical antifungals on the market, including ciclopirox, a new drug sertaconazole, and even OTC drugs such as terbinafine. All of these drugs can be used to treat tinea pedis. Oral antifungal therapy also can be used for the treatment of tinea pedis. Patients can take ultramicrosized griseofulvin for approximately 6 weeks. Although griseofulvin commonly is thought of as a long-term treatment (approximately 18 months) for onychomycosis, it is actually a relatively short-term therapy. Terbinafine and itraconazole are exceptionally effective in treating tinea pedis. Although the drugs have no specific indications, short courses (2 3 weeks of terbinafine or a single pulse of the itraconazole) will clear up tinea pedis. ASiM: Case 3 is a patient who tested positive for HIV. You mention that these patients are prone to developing onychomycosis. If they already are taking several drugs to treat HIV, why is it important to treat the nail fungus? Dr Joseph: I think treatment is important because of the psychosocial issues connected with onychomycosis. Nail fungus is a strong indicator that a patient has HIV. Nail fungus is a unique condition in patients with HIV, and they often develop proximal subungual onychomycosis. Patients with HIV and the coimmunity associated with HIV/AIDS know that onychomycosis is a marker for HIV. Therefore, having onychomycosis really screams, I m HIV positive, I may have AIDS. Also, onychomycosis could serve as a source of infection. Patients with HIV or AIDS are prone to systemic fungal infections. No data are available to support this statement, but I think that physicians who have patients with HIV or AIDS would want to treat and cure a fungus to eliminate the risk of fungus becoming systemic. The patients with HIV whom I ve seen clinically have been amenable to having the onychomycosis treated. However, I don t treat large numbers of patients with HIV; perhaps physicians who do may look at this differently. ASiM: Case 4 was a patient who was taking several medications. In terms of the medications available for treating onychomycosis, what drug interactions should prescribers be concerned about? Dr Joseph: In this situation, physicians may be too cautious about drug-to-drug interactions. For example, azoles in particular itraconazole is a potent inhibitor of cytochrome P450 isoenzyme 3A4 and will effect many drug-to-drug interactions. The package insert even contains a large number of black-box Advanced Studies in Medicine S617
5 warnings. Many common drugs, including the statins prescribed for patients with high cholesterol, are metabolized by enzyme 3A4. Therefore, there is potential for drug-to-drug interactions with a drug that is a potent inhibitor of enzyme 3A4. There is a list available for prescribing itraconazole (Table 1). 7 Terbinafine is not an inhibitor of 3A4, thus there are no drug-to-drug interactions that occur with some of the other oral antifungals. Terbinafine instead inhibits isoenzyme 2D6, which metabolizes fewer drugs than 3A4. SSRIs or the β-blocker propranolol are examples of drugs that are 2D6-metabolized. Patients, especially those patients who take psychotropic drugs, such as antidepressants or antiseizure medications, should be observed for any sign of health-related changes because of drugto-drug interaction (Table 2). 8 Interestingly, there is no black-box warning for SSRIs, and I m not aware of any clinically significant cases that have been reported in the literature, but theoretically drug-to-drug interactions are a possibility. Clinically, there are few drug-to-drug interactions, and I mentioned the statins only because so many patients are taking them. ASiM: Is it possible for an infection to be so advanced that it s no longer treatable, as shown in Case 5? Dr Joseph: Overall, this is not a common occurrence. If the nail has been dystrophic, thick and painful, and causing pressure on the nail bed, the cells of the nail matrix may be destroyed over a prolonged period. In this scenario, the infection could cause so much damage to the underlying structures of the nail that nothing can be done to save the nail because it is not growing appropriately. There are cases in which the fungus can be mycologically cured, but the nail is not Table 1. Selected Drug Interactions with Itraconazole* Drug plasma concentration increased by itraconazole Antiarrhythmics Digoxin, dofetilide, quinidine, disopyramide Anticonvulsants Carbamazepine Antimycobacterials Rifabutin Antineoplastics Busulfan, docetaxel, vinca alkaloids Antipsychotics Pimozide Benzodiazepines Alprazolam, diazepam, midazolam, triazolam Calcium channel blockers Dihydropyridines and verapamil Gastrointestinal motility agents Cisapride HMG CoA-reductase inhibitors Atorvastatin, cerivastatin, lovastatin, simvastatin Immunosuppressants Cyclosporine, tacrolimus, sirolimus Oral hypoglycemics Oral hypoglycemics Protease inhibitors Indinavir, ritonavir, saquinavir Other Levacetylmethadol (levomethadyl), ergot alkaloids, halofantrine, alfentanil, buspirone, methylprednisolone, budesonide, dexamethasone, trimetrexate, warfarin, cilostazol, eletriptan Anticonvulsants Antimycobacterials Gastric acid suppressors/neutralizers Non-nucleoside reverse transcriptase inhibitors Macrolide antibiotics Protease inhibitors Decrease plasma concentration of itraconazole Table 2. Drug Interactions with Terbinafine The following classes of drugs are metabolized predominantly by CYP 2D6. They should be administered with careful monitoring and may require reduced doses when administered with terbinafine. Tricyclic antidepressants Selective serotonin reuptake inhibitors β blockers Monoamine oxidase inhibitors type B No information is available from adequate drug-to-drug interaction studies for oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, and calcium channel blockers. Data from Terbinafine US prescribing information. 8 Carbamazepine, phenobarbital, phenytoin Isoniazid, rifabutin, rifampin Antacids, H 2 -receptor antagonists, proton pump inhibitors Nevirapine Increase plasma concentration of itraconazole Clarithromycin, erythromycin Indinavir, ritonavir *This list is not all-inclusive. Contraindicated with itraconazole based on clinical and/or pharmacokinetic studies. Reprinted with permission from Itraconazole US prescribing information. Available at: Accessed May 3, S618 Vol. 5 (6D) June 2005
6 going to be restored to any form of normalcy because it has been dystrophic for such an extended time. Some patients strongly object to their toenails being removed, but patients can function quite well without the infected toenails. REFERENCES 1. Joseph WS, Scher RK. Understanding the Realities of Antifungal Therapy. Podiatry Today. 2004;17(11a). 2. Gupta AK, Lynch LE. Management of onychomycosis: examining the role of monotherapy and dual, triple, or quadruple therapies. Cutis. 2004;74(suppl 1): Tosti A, Piraccini BM, Stinchi C, Colombo MD. Relapses of onychomycosis after successful treatment with systemic antifungals: a three-year follow-up. Dermatology. 1998; 197: Heikkila H, Stubb S. Long-term results in patients with onychomycosis treated with terbinafine or itraconazole. Br J Dermatol. 2002;146: Jansen R, Redekop WK, Rutten FF. Cost effectiveness of continuous terbinafine compared with intermittent itraconazole in the treatment of dermatophyte toenail onychomycosis: an analysis based on results from the L.I.ON. study. Lamisil versus Itraconazole in Onychomycosis. Pharmacoeconomics. 2001;19: Sigurgeirsson B, Olafsson JH, Steinsson JB, et al. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol. 2002;138: Itraconazole US prescribing information. Sporanox (Itraconazole) Capsules Web site. Available at: px/sporanox.pdf. Accessed May 3, Terbinafine US prescribing information. Novartis Pharmaceuticals Corporation Web site. Available at: isil_tablets.pdf. Accessed May 3, Advanced Studies in Medicine S619
Core Safety Profile. Pharmaceutical form(s)/strength: Oral solution 10 mg /ml. Date of FAR:
Core Safety Profile Active substance: Itroconazole Pharmaceutical form(s)/strength: Oral solution 10 mg /ml P - RMS: UK/H/PSUR/0033/001 Date of FAR: 15.07.2010 CORE SAFETY PROFILE Based on EU SmPC sections
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Concentrate and solvent for solution for infusion, 10mg/ml. Date of FAR:
Core Safety Profile Active substance: Itroconazole Pharmaceutical form(s)/strength: Concentrate and solvent for solution for infusion, 10mg/ml P - RMS: UK/H/PSUR/0033/001 Date of FAR: 15.07.2010 CORE SAFETY
More informationITRANOX. Composition Each capsule contains :
ITRANOX Composition Each capsule contains : Itraconazole 100 mg Capsules Action Itraconazole is a synthetic triazole derivative. When administered orally, it has shown fungistatic activity against superficial
More informationCatamaran Prior Authorization Department. Phone: Fax: Prescriber Information. Member Information.
Prescriber Information Last Name First Name DEA / NPI Specialty Phone Member Information Last Name Fax - - - - First Name Member ID Number DOB Medication Information: Drug Name and Strength: Quantity:
More informationClassification. Distal & Lateral Subungual OM. White Superficial OM. Proximal Subungual OM. Candidal OM. Total dystrophic OM
Onychomycosis Commonest dermatological condition Definition: Infection of the nail caused by fungi that include dermatophytes, non-dermatophyte moulds and yeasts (mainly Candida). 80% of all OM affects
More informationSPORANOX Capsules Itraconazole Consumer Medicine Information
SPORANOX Capsules Itraconazole Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about SPORANOX capsules. It does not contain all the available information.
More informationAPO-ITRACONAZOLE Itraconazole capsules
APO- Itraconazole capsules Consumer Medicine Information For a copy of a large print leaflet, Ph: 1800 195 055 WHAT IS IN THIS LEAFLET This leaflet answers some common questions about APO-. It does not
More informationREGIONAL ADMINISTRATIVE INFORMATION. 3. Pharmaceutical form Capsule, hard Elongated, red opaque hard gelatine capsule (size 0)
MODULE 1: Module 1.3.1 REGIONAL ADMINISTRATIVE INFORMATION Summary of Product Characteristics 1. Name of the medicinal product 2. Qualitative and quantitative composition Each capsule contains 100 mg of
More informationREGIONAL ADMINISTRATIVE INFORMATION
MODULE 1: Module 1.3.1 REGIONAL ADMINISTRATIVE INFORMATION Summary of Product Characteristics 1. Name of the medicinal product 2. Qualitative and quantitative composition Each capsule contains 100 mg of
More informationClinical Trial Designs for Topical Antifungal Treatments of Onychomycosis and Implications on Clinical Practice
Clinical Trial Designs for Topical Antifungal Treatments of Onychomycosis and Implications on Clinical Practice Phoebe Rich, MD; Tracey C. Vlahovic, DPM; Warren S. Joseph, DPM; Lee T. Zane, MD; Steve B.
More informationNizoral 200 mg tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER Nizoral 200 mg tablets Ketoconazole Nizoral is a registered trademark Read all of this leaflet carefully before you start using this medicine. Keep this leaflet.
More informationFungal Resistance, Biofilm, and Its Impact In the Management of Nail Infection
Fungal Resistance, Biofilm, and Its Impact In the Management of Nail Infection Faculty Raza Aly, PhD, MPH Professor Emeritus University of California Medical Center (MSSF) Professor, Dermatology Faculty
More informationRead all of this leaflet carefully before you start taking your medicine:
PACKAGE LEAFLET: INFORMATION FOR THE USER Sporanox 10mg/ml Oral Solution (itraconazole) Read all of this leaflet carefully before you start taking your medicine: Keep this leaflet. You may need to read
More informationBefore you take ITRACAP. When you must not take it
ITRACAP Itraconazole CONSUMER MEDICINE INFORMATION What is in this leaflet This leaflet answers some common questions about ITRACAP Itraconazole capsules. It does not contain all the available information.
More informationPRODUCT INFORMATION. DAKTARIN Oral Gel
PRODUCT INFORMATION DAKTARIN Oral Gel NAME OF THE MEDICINE Miconazole DESCRIPTION [Miconazole, 1-(2(2,4-dichlorophenyl)-2-(2,4-dichlorophenyl)methoxy]ethyl)-1H-imidazole, is a synthetic 1-phenethyl-imidazole
More informationRESULTS. TABLE 1 FOOT, TOE, AND TOENAIL EXAMINATION CONDITION (Number of patients with)
Over the several decades that I have been in practice I have been struggling to provide my patients with onychomycosis an effective treatment for this pervasive and embarrassing disease. I have had several
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Sporanox 100 mg capsules. Itraconazole
PACKAGE LEAFLET: INFORMATION FOR THE USER Sporanox 100 mg capsules Itraconazole Read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may need to read it again
More informationConcomitant antiretroviral therapy : Avifanz must be given in combination with other antiretroviral medications.
Avifanz Tablet Description Avifanz is the brand name for Efavirenz. Efavirenz, a synthetic antiretroviral agent, is a non-nucleoside reverse transcriptase inhibitor. While Efavirenz is pharmacologically
More informationDISTAL LATERAL SUBUNGUAL ONYCHOMYCOSIS
Boni E. Elewski, MD James Elder Professor of Dermatology University of Alabama RESEARCH GRANTS -TO UNIVERSITY Dusa, Meiji, Valeant, Viamet Amgen, Abbvie, Boehringer Ingelheim, Celgene, Lilly, Merck, Novartis,
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Itrakonazol Actavis 100 mg, hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule, hard contains 100 mg of itraconazole.
More informationSource of effectiveness data The effectiveness evidence was derived from a systematic review of published studies.
Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States Gupta A K Record Status This is a critical
More informationMedical Directive. Medical Director: Date Revised: January 23, Executive Director: Date Revised: January 23, 2019
Medical Directive Assessment and Treatment of Onychomycosis and Tinea Pedis Assigned Number: 026 Activation Date: January 1, 2019 Review due by: December 1, 2020 Approval Signature & Date Medical Director:
More informationOnychomycosis and tinea pedis in patients with diabetes
PUBLICATION OF THIS ARTICLE WAS SUPPORTED BY AN EDUCATIONAL GRANT FROM NOVARTIS PHARMACEUTICALS CORPORATION Onychomycosis and tinea pedis in patients with diabetes Phoebe Rich, MD Portland, Oregon ONYCHOMYCOSIS
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 1Q18 January February
BRAND NAME Prevymis TM GENERIC NAME Letermovir MANUFACTURER Merck & Co., Inc. DATE OF APPROVAL November 9, 2017 PRODUCT LAUNCH DATE TBD REVIEW TYPE Review type 1 (RT1): New Drug Review Full review of new
More informationClinical clearing of moderate and severe onychomycosis with the Nd:YAG 1064nm laser and post treatment prevention with tolnaftate
Clinical clearing of moderate and severe onychomycosis with the Nd:YAG 1064nm laser and post treatment prevention with tolnaftate by Myron A. Bodman DPM 1*, Marie Mantini Blazer DPM 1, Bryan D. Caldwell
More informationPage 1 of 5 Management strategies for onychomycosis in special patient populations Phoebe Rich, Nathaniel J. Jellinek and David M. Pariser Dermatology News. 46.8 (Aug. 2015): ps13. Copyright: COPYRIGHT
More informationTo understand the formulary process from the hospital perspective
Formulary Process Michael A. Militello, Pharm.D. Cleveland Clinic Cleveland Clinic 2011 Goal and Objectives To understand the formulary process from the hospital perspective p To list the various panels
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Onmel, Sporanox) Reference Number: CP.CPA.134 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this
More informationRecommended dosing for pediatric patients (6 months to 12 years of age) 1. Dose based on lopinavir component* 1.25 ml ml
Abbott Virology 100 Abbott Park Road Abbott Park, IL 60064 KALETRA 100/25 mg tablets NDC #0074-0522-60 Dear Healthcare Provider: Introducing a new strength of KALETRA (lopinavir/ritonavir): 100/25 mg tablets
More informationItraconazole DIGICON. Composition: MOLECULAR INTRODUCTION
Itraconazole DIGICON Composition: Itraconazole 100 mg MOLECULAR INTRODUCTION Itraconazole is a triazole medicine used to treat fungal infections. It is effective against a broad spectrum of fungi including:
More informationSPORANOX Capsules Janssen
SPORANOX Capsules Janssen NAME OF THE MEDICINAL PRODUCT SPORANOX CAPSULES QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 100 mg itraconazole in a pellet formulation. PHARMACEUTICAL FORM
More informationRifamycins Drug interactions
Rifamycins Drug interactions Drug Category Drug / Drug Class Antacids Nature of Interaction absorption of rifamycins Recommendations Give 1 hour prior to Antacid use Acid Blocking Agents Proton Pump Inhibitors
More informationNational AIDS Treatment Advocacy Project
National AIDS Treatment Advocacy Project Nelfinavir: general information, study results (CD4 and viral load), dosing schedule, eating instructions, drug interactions, combination with other protease inhibitors
More informationSPORANOX Capsules Itraconazole
SPORANOX Capsules Itraconazole Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about SPORANOX capsules. It does not contain all the available information.
More informationAntifungal drugs Dr. Raz Muhammed
Antifungal drugs 13. 12. 2018 Dr. Raz Muhammed 2. Flucytosine (5-FC) Is fungistatic Is a synthetic pyrimidine antimetabolite Is often used in combination with amphotericin B in the treatment of systemic
More informationPART III: PATIENT MEDICATION INFORMATION READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE
PART III: PATIENT MEDICATION INFORMATION READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE Pr BIAXIN XL clarithromycin extended-release tablets Manufacturer s Standard Read this carefully before you
More informationUPDATE ON ONYCHOMYCOSIS TREATMENTS
UPDATE ON ONYCHOMYCOSIS TREATMENTS Tracey C. Vlahovic, DPM FFPM RCPS (Glasg) Clinical Professor, Dept. of Podiatric Medicine Temple University School of Podiatric Medicine, Philadelphia, PA CONFLICTS OF
More informationCorporate Medical Policy
Corporate Medical Policy Laser Treatment of Onychomycosis File Name: Origination: Last CAP Review: Next CAP Review: Last Review: laser_treatment_of_onychomycosis 5/2013 11/2017 11/2018 11/2017 Description
More informationAnnotation Guidelines
Annotation Guidelines Henk Harkema, Richard Boyce, Rob Guzman Version 1.9, 12/21/10 Introduction The purpose of this document is to provide instructions for the manual annotation of drug package inserts
More informationThe US Onychomycosis Market (2017 Edition) July 2017
The US Onychomycosis Market (2017 Edition) July 2017 The US Onychomycosis Market Report Scope of the Report The report entitled The US Onychomycosis Market (2017 Edition), provides analysis of the US onychomycosis
More informationDrug Interactions Year 2 Clinical Pharmacology
1 Drug Interactions Year 2 Clinical Pharmacology Prof Mark McKeage Department of Pharmacology & Clinical Pharmacology 2 Objectives Explain the potential for interacting drugs to cause beneficial and harmful
More informationCCDS 09/2010 Page 1 of 19
PACKAGE INSERT SCHEDULING STATUS Schedule 4 PROPRIETARY NAME (and dosage form) SPORANOX 10 mg/ml Oral solution. COMPOSITION Each millilitre oral solution contains 10 mg of itraconazole. Sporanox Oral solution
More informationJanssen NAME OF THE MEDICINAL PRODUCT
NIZORAL Tablets Janssen NAME OF THE MEDICINAL PRODUCT NIZORAL Tablets QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 200 mg ketoconazole. For excipients, see List of Excipients PHARMACEUTICAL
More informationAFPC Conference InterMed-Rx : Harmony and optimal therapy in the use of medication. June
AFPC Conference 2009 InterMed-Rx : Harmony and optimal therapy in the use of medication June 5 2009 Jacques Turgeon, B.Pharm., Ph.D. Full professor, Faculty of pharmacy Research Director, CHUM Université
More informationBefore you take Itrazole
NEW ZEALAND CONSUMER MEDICINE INFORMATION ITRAZOLE Itraconazole capsule 100 mg What is in this leaflet This leaflet answers some common questions about It does not contain all the available information.
More informationONYCHOMYCOSIS LASER THERAPY
FOX ONYCHOMYCOSIS LASER THERAPY 1064 nm FOX 1064 nm, 10W IDEAL FOR: ONYCHOMYCOSIS FUNGAL NAIL INFECTION LASER INNOVATION MADE IN GERMANY www.arclaser.com 2 FOX Laser offers an effective, pain free method
More informationKentucky Department for Medicaid Services. Drug Review Options
Kentucky Department for Medicaid Services Drug Review Options The following chart lists the agenda items scheduled and the options submitted for review at the November 21, 2013 meeting of the Pharmacy
More informationHow to cure toenail fungus
P ford residence southampton, ny How to cure toenail fungus What Makes Zeta Clear The Best Fungal Nail Treatment. Zeta Clear is more effective than any other toenail fungus cream or home treatment out
More informationPART III: PATIENT MEDICATION INFORMATION READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE. clarithromycin for oral suspension USP
PART III: PATIENT MEDICATION INFORMATION READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE Pr BIAXIN clarithromycin for oral suspension USP Read this carefully before you start taking BIAXIN and each
More informationSporanox 100 mg capsules
PACKAGE LEAFLET: INFORMATION FOR THE USER Sporanox 100 mg capsules Itraconazole Sporanox is a registered trademark Read all of this leaflet carefully before you start taking this medicine because it contains
More informationWho remembers Terfenadine? Once daily non-sedating anti-histamine. Drug Interactions: What is the CYP 450 system? What does the CYP 450 system do?
Drug Interactions: Things that go BOOM! Who remembers Terfenadine? Once daily non-sedating anti-histamine Amelie Hollier, DNP, FNP-BC, FAANP Advanced Practice Education Associates A strange thing happened
More informationPage 1 of 9 Current and emerging options in the treatment of onychomycosis Boni Elewshi, David Pariser, Phoebe Rich and Richard K. Scher Family Practice News. 43.14 (Sept. 1, 2013): ps11. Copyright: COPYRIGHT
More informationLaser Treatment of Onychomycosis. Description
Subject: Laser Treatment of Onychomycosis Page: 1 of 8 Last Review Status/Date: September 2014 Laser Treatment of Onychomycosis Description Onychomycosis is a common fungal infection of the nail. Currently
More informationSelf Assessment Question 1
Drug Interactions Bruce G. Pollock, M.D., Ph.D. Professor of Psychiatry, Pharmacology and Nursing Chief, Academic Division of Geriatrics and Neuropsychiatry University of Pittsburgh Medical Center 1 Self
More informationThe Nail Common terms & Anatomy Onychomycosis Causes and Background Onychomycosis Classification Treatment Basics
FOX Podiatry Applications The Nail Common terms & Anatomy Onychomycosis Causes and Background Onychomycosis Classification Treatment Basics The Nail - Areas definitions Proximal nail fold Nail plate area
More informationClinical Practice Guideline Superficial Fungal Infection
Clinical Practice Guideline Superficial Fungal Infection ก ก ก กก ก ก ก ก กก ก ก ก ก ก ก ก ก ก ก ก ก ก ก ก ก ก ก * ก Superficial fungal infection ก 1. ก (Pityriasis versicolor, Tinea versicolor) 2. ก ก
More informationInvestor Presentation December 2012
Investor Presentation December 2012 1 Safe Harbor Statement Certain items in this presentation and other matters discussed today or answers that may be given to questions asked could constitute forwardlooking
More informationJ. Hibler, D.O. OhioHealth - O Bleness Memorial Hospital, Athens, Ohio. AOCD Annual Conference Orlando, Florida
J. Hibler, D.O. OhioHealth - O Bleness Memorial Hospital, Athens, Ohio AOCD Annual Conference Orlando, Florida 10.18.15 A) Onychodystrophy B) Onychogryphosis Question dogma Michael Conroy, MD C) Onychomycosis
More informationTherapeutics for the Clinician. Efinaconazole Solution 10%: Topical Antifungal Therapy for Toenail Onychomycosis CUTIS
Solution 10%: Topical Antifungal Therapy for Toenail Onychomycosis Antonella Tosti, MD Practice Points Toenail onychomycosis is a common disease with limited treatment options, as treatment failures and
More informationANTI-HIV DRUG INTERACTIONS. a guide to the interactions found between anti-hiv drugs and common hiv-related therapies
ANTI-HIV DRUG INTERACTIONS! a guide to the interactions found between anti-hiv drugs and common hiv-related therapies A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS
More informationDarunavir (Prezista) FACTSHEET. Summary. How do people with HIV/AIDS use darunavir? What is darunavir? How does darunavir work?
FACTSHEET Darunavir (Prezista) Summary Darunavir is a type of anti-hiv drug called a protease inhibitor. Common side effects of darunavir can include nausea, diarrhea and headache. It is taken at a dose
More informationFactSHEET. DARUNAVIR (Prezista) Summary. What is darunavir? How do people with HIV/AIDS use darunavir? How does darunavir work?
FactSHEET DARUNAVIR (Prezista) Summary Darunavir is a type of anti-hiv drug called a protease inhibitor. Common side effects of darunavir can include nausea, diarrhea and headache. It is taken at a dose
More informationInitiation Guide. Images not actual size.
Initiation Guide Images not actual size. INDICATIONS AND USAGE SYMDEKO is indicated for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation
More informationPART III: PATIENT MEDICATION INFORMATION READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE. Clarithromycin tablets, film-coated
PART III: PATIENT MEDICATION INFORMATION READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE Pr Sandoz Clarithromycin Clarithromycin tablets, film-coated Read this carefully before you start taking Sandoz
More informationMerz North America (Merz Aesthetics, Inc. and Merz Pharmaceuticals, LLC) Announces the End of Court-Ordered Injunction
PRESS RELEASE Merz North America (Merz Aesthetics, Inc. and Merz Pharmaceuticals, LLC) Announces the End of Court-Ordered Injunction Greensboro, N.C. (BUSINESS WIRE) Merz North America (Merz Aesthetics,
More informationBackground 1/29/2018. Lasers and Lights for Onychomycosis KEYVAN NOURI, MD. Keyvan Nouri, M.D. White superficial. onychomycosis
Lasers and Lights for Onychomycosis KEYVAN NOURI, MD Keyvan Nouri, M.D. Professor of Dermatology, Ophthalmology, Otolaryngology & Surgery Louis C. Skinner, Jr., M.D. Endowed Chair in Dermatology Richard
More informationDarunavir (Prezista) FACT SHEET. Summary. What is darunavir? How does darunavir work? How do people with HIV use darunavir?
Darunavir (Prezista) Summary Darunavir is a type of anti-hiv drug called a protease inhibitor. Common side effects of darunavir can include nausea, diarrhea and headache. It is taken at a dose of 600 mg
More informationLUZU (luliconazole) external cream
LUZU (luliconazole) external cream Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other EFINACONAZOLE JUBLIA 41184 TAVABOROLE KERYDIN 41353 GUIDELINES FOR USE 1. Does the patient have a diagnosis of onychomycosis of the fingernail or toenail? If yes,
More informationOnychomycosis is a fungal nail infection that takes a significant
ORIGINAL RESEARCH High Frequency of Itraconazole Prescriptions with Potentially Interacting Medications in a Large Health Care Plan OBJECTIVE: The objective of this study was to determine the frequency
More informationClinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents
INVITED ARTICLE REVIEWS OF ANTI-INFECTIVE AGENTS Louis D. Saravolatz, Section Editor Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents Roger
More informationPapers. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis
Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis E Glyn V Evans, Bárdur Sigurgeirsson for the LION study group Abstract
More informationAlabama Medicaid DUR Board Meeting Minutes October 22, 2008
Alabama Medicaid DUR Board Meeting Minutes October 22, 2008 Members Present: Gurinder Doad, Paula Thompson, Rhonda Harden, Kevin Green, Bernie Olin, Clemice Hurst, Kelli Littlejohn, Kevin Royal, Tiffany
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER
Dear Patient! You have been prescribed Terbinafine "Genericon" 250 mg - tablets by your doctor, who, in the interests of improving your state of health, considers this product to be suitable for the treatment
More information104 MMWR December 17, 2004
104 MMWR December 17, 2004 TABLE 8. Substantial pharmacokinetic drug-drug interactions for drugs used in the treatment of opportunistic Drugs Interacting with Mechanism/effects Recommendations Acyclovir
More informationDrug Intractions Alessandro Nobili Luca Pasina Claudia Braun What does the term drug interaction mean?
Drug Intractions edited by Alessandro Nobili e Luca Pasina Laboratorio di valutazione della Qualità delle Cure e dei Servizi per l Anziano Servizio Informazione sui Farmaci nell Anziano Translated and
More informationFlukonazol 50mg Capsules, 150mg Capsules
PACKAGE LEAFLET: INFORMATION FOR THE USER Flukonazol 50mg Capsules, 150mg Capsules FLUCONAZOLE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine,
More informationA class IIa medical device intended for mild-to-moderate fungal nail infection PRODUCT MONOGRAPH
A class IIa medical device intended for mild-to-moderate fungal nail infection PRODUCT MONOGRAPH AWB-2052628721 Date of Preparation March 2017 Introduction to Bayer Bayer is a Life Science company with
More informationPatient Information leaflet
Patient Information leaflet CARDISEC (90 MG, 120 MG AND 180 MG) DILTIAZEM HYDROCHLORIDE PROLONGED- RELEASE CAPSULES USP) Read all of this leaflet carefully before you start taking this medicine because
More informationPRODUCT MONOGRAPH. fosamprenavir calcium tablet, 700 mg fosamprenavir. fosamprenavir calcium oral suspension, 50 mg/ml fosamprenavir
PRODUCT MONOGRAPH Pr TELZIR fosamprenavir calcium tablet, 700 mg fosamprenavir fosamprenavir calcium oral suspension, 50 mg/ml fosamprenavir Antiretroviral Agent ViiV Healthcare ULC 245, boulevard Armand-Frappier
More informationRevised: 3/2018 due to the risk of severe hepatotoxicity. (4)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use INVIRASE safely and effectively. See full prescribing information for INVIRASE. INVIRASE (saquinavir
More informationClinical Policy: Itraconazole (Onmel, Sporanox) Reference Number: ERX.NPA.25 Effective Date:
Clinical Policy: (Onmel, Sporanox) Reference Number: ERX.NPA.25 Effective Date: 06.01.15 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS Page 1 of 30 1. NAME OF THE MEDICINAL PRODUCT mg/100mg Tablets * 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains atazanavir sulfate equivalent to 300
More informationPRESS RELEASE. Merz North America Announces Change In U.S. Aesthetics (Merz Aesthetics, Inc.) Leadership
PRESS RELEASE Merz North America Announces Change In U.S. Aesthetics (Merz Aesthetics, Inc.) Leadership Greensboro, N.C. (BUSINESS WIRE) Merz North America today announced that Jim Hartman has been appointed
More informationDaclatasvir (Daklinza ) Drug Interactions with HIV Medications
Daclatasvir/Sofosbuvir (Daklinza /Sovaldi TM ) Drug Interactions A Quick Guide for Clinicians April 2017 John J Faragon, PharmD, BCPS, AAHIVP Mechanism of Action and Route of Metabolism for Daclatasvir
More informationoverview of current strategies for monotherapy and combination therapy
ORIGINAL ARTICLE JEADV (2005) 19, 21 29 DOI: 10.1111/j.1468-3083.2004.00988.x Topical antifungal drugs for the treatment of onychomycosis: an Blackwell Publishing, Ltd. overview of current strategies for
More informationPART III: CONSUMER INFORMATION
PART III: CONSUMER INFORMATION Pr REYATAZ atazanavir capsules (as atazanavir sulfate) This leaflet is Part III of a three-part Product Monograph published when REYATAZ was approved for sale in Canada and
More informationTreatments for stroke prevention in Atrial Fibrillation as recommended by the Canadian Cardiovascular Society
Treatments for stroke prevention in Atrial Fibrillation as recommended by the Canadian Cardiovascular Society Coumadin (Warfarin) Does this medication need ongoing monitoring of blood clotting times? Yes.
More informationSPORANOX Oral Solution Itraconazole
SPORANOX Oral Solution Itraconazole Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about SPORANOX Oral Solution. It does not contain all the available
More informationSUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other TELAPREVIR INCIVEK 37629 This drug requires a written request for prior authorization. All requests for hepatitis C medications require review by a pharmacist prior
More informationAdverse drug interactions in dental practice
University "Goce Delchev" Shtip Faculty of Medical science Adverse drug interactions in dental practice Assistant professor Mаrija Darkovska-Serafimovska INTERACTION interaction is a situation in which
More informationDoes terbinafine cause weight gain
Does terbinafine cause weight gain Lamisil ( terbinafine ) rapid weight gain,. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information. Common Questions
More informationAbstract. OBJECTIVE--To compare the efficacy and safety of terbinafine 1% cream and clotrimazole 1% cream in the treatment of tinea pedis.
Abstract. OBJECTIVE--To compare the efficacy and safety of terbinafine 1% cream and clotrimazole 1% cream in the treatment of tinea pedis. DESIGN-- Multicentre, double blind parallel group study. SETTING--32
More informationDrug Interactions Year 2 Clinical Pharmacology
1 Drug Interactions Year 2 Clinical Pharmacology Dr Susannah O Sullivan Department of Pharmacology University of Auckland 2 Objectives Explain the potential for interacting drugs to cause beneficial and
More informationSTUDY. A New Classification System for Grading the Severity of Onychomycosis
STUDY A New Classification System for Grading the Severity of Onychomycosis Onychomycosis Severity Index Caitlin Carney, MD; Antonella Tosti, MD; Ralph Daniel, MD; Richard Scher, MD; Phoebe Rich, MD; Jamie
More informationEfavirenz Mylan 600 mg Film-coated Tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER Efavirenz Mylan 600 mg Film-coated Tablets (efavirenz) Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationTRANSPARENCY COMMITTEE OPINION. 27 January 2010
The legally binding text is the original French version TRAPARENCY COMMITTEE OPINION 27 January 2010 80 mg/g, medicated nail lacquer B/1 glass vial of 3.3 ml (CIP: 395 010-4) B/1 glass vial of 6.6 ml (CIP:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT INVIRASE 200 mg hard capsules. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One capsule contains 200 mg of saquinavir as saquinavir
More information